Is Weed Legal in Switzerland? Understanding Switzerland Cannabis and Marijuana Laws (2026)

Switzerland permits medical cannabis on prescription and regulates low-THC products separately from controlled cannabis. Recreational cannabis with a total THC content of 1% or more remains prohibited outside authorized scientific trials. Possession of up to 10 grams for personal use is not punishable, but consumption can still attract a fine. A proposed national Cannabis Products Act has not yet opened a general adult-use market.

Is cannabis legal in Switzerland?

The Federal Office of Public Health (FOPH) distinguishes controlled cannabis from products below the 1% total-THC threshold. The main categories are:

• Medical cannabis: prescribed treatment under the medical regulatory framework.
• Low-THC products: outside narcotics control when below 1%, but still subject to their product-category rules.
• Non-medical cannabis at 1% THC or above: generally prohibited, with limited scientific-trial exceptions.

Neither the small-possession rule nor a low-THC label is a universal permission to grow, sell, import or consume a product. The purpose and the activity matter as well as its composition.

Is medical cannabis legal in Switzerland?

Yes. Since August 1, 2022, doctors have been able to prescribe cannabis medicines without an individual exceptional licence from the FOPH. Treatment can include pharmacy-made preparations. This change removed a federal authorization step; it did not make medical cannabis an over-the-counter product or create a patient home-growing entitlement.

The FOPH’s medical guidance describes use for symptoms such as chronic pain, spasticity and chemotherapy-related nausea or appetite loss. Treatment decisions belong with the prescriber. Legal availability does not establish that cannabis is suitable or effective for every patient.

Compulsory health insurance generally reimburses these treatments only in exceptional cases. Patients should clarify coverage before filling a prescription. Doctors report treatment data during the first two treatment years, under a collection programme limited to 2029.

Commercial cultivation, manufacture and trade for medical purposes fall under Swissmedic’s licensing and control system. Medical supply and scientific non-medical trials are separate regulatory routes.

Is recreational cannabis legal in Switzerland?

No. Recreational cannabis containing 1% THC or more is illegal in Switzerland for the general public. Growing, importing, producing and selling it is prohibited, and the only place adults can legally buy regulated cannabis for non-medical use is inside an authorised scientific pilot trial. The FOPH is explicit that, outside those trials, the ban on cannabis remains fully in force.

What sets Switzerland apart is that it has chosen to test regulated access through controlled experiments rather than leaving the question to the illicit market alone. Those trials, described in more detail below, are designed to produce hard data for the national legalisation bill now moving through parliament.

What are the penalties for cannabis in Switzerland?

Federal health guidance separates possession from consumption: possessing up to 10 grams for one’s own use is not punishable, while adult consumption can attract a CHF 100 fixed fine. Juvenile criminal law applies to minors. It is misleading to say that everyone caught with a small amount owes CHF 100.

Outside the simplified procedure, the circumstances matter. Personal-use conduct is distinguished from unauthorized supply under the Narcotics Act. A quantity above 10 grams does not, by itself, prove trafficking. Unauthorized dealing or production can carry imprisonment or a monetary penalty, and aggravated offences are treated more severely.

The non-punishable-possession rule does not establish a legal retail source or authorize driving after cannabis use. Patients should discuss fitness to drive with their clinician; a product being legally obtained does not mean it is safe to use before driving.

Is CBD legal in Switzerland?

Some CBD products can be sold legally, but being below 1% total THC is only the narcotics-law test. Food, medicine, cosmetics and smoking-product rules still apply. A bottle of CBD oil is not automatically lawful because its THC content is low.

The Federal Food Safety and Veterinary Office classifies cannabinoids and cannabinoid-containing hemp extracts as novel foods requiring the relevant Swiss authorization or European Commission approval before marketing as food. Ordinary hemp seeds, seed oil and seed flour have a different history of food use; they should not be equated with CBD extracts. Food-specific THC limits also apply.

Joint regulatory guidance explains that low-THC herbal smoking products and CBD e-cigarettes fall under tobacco-product legislation. Product notifications, labelling and other requirements remain relevant. Products presented as treatments must meet the applicable therapeutic-products rules.

Is hemp legal in Switzerland?

Low-THC hemp below the narcotics threshold can be cultivated, but the intended use and finished product still determine which other rules apply. A crop being outside narcotics control does not authorize every resulting food, cosmetic or medicinal product.

Switzerland’s threshold is not a border allowance. A product lawfully purchased there may be restricted in a neighbouring country. EU agricultural hemp thresholds also should not be confused with a single European rule for retail flower, CBD oils or foods.

Switzerland’s recreational cannabis pilot trials

The pilot-trial framework took effect on May 15, 2021 and runs for ten years. An individual trial is ordinarily limited to five years, with a possible one-off extension of up to two years. The federal authority approves trials; the projects themselves are conducted by public or private organizations with research institutions.

Participants must be adults who already use cannabis, meet residency and health criteria, and consent to research. Each study can impose additional eligibility requirements. Products are for the participant’s own use, not for resale or sharing. These are not tourist dispensaries.

The official overview lists eight authorized projects:

• WeedCare: Basel-Stadt, testing pharmacy distribution.
• Züri Can: the city of Zurich, comparing pharmacies, social clubs and other supply points.
• SCRIPT: Bern, Biel and Lucerne.
• Cann-L: Lausanne.
• La Cannabinothèque: Vernier.
• Grashaus Projects: Liestal and Allschwil.
• Cannabis Research Zürich: a separate canton-level study.
• CanLeg: St. Gallen, including research on online ordering and delivery.

Züri Can should not be called Switzerland’s largest trial: its federal listing gives a planned sample of 3,000, while CanLeg’s listing gives 5,000 and a planned May 2026–May 2031 duration. Those are planned study sizes, not verified current enrolment totals. CanLeg’s delivery model does not authorize nationwide cannabis mail order.

What do the preliminary trial findings show?

The overarching evaluation published in January 2026 covers findings through July 2025 from seven trials, involving approximately 10,500 participants. It therefore does not describe results from all eight projects now listed.

The FOPH reports good acceptance of regulated access, no observed increase in consumption and signs of movement toward lower-risk products. These are encouraging preliminary findings in selected existing users. They do not establish that cannabis is harmless, resolve long-term health outcomes or show what unrestricted access would do across the entire population. The trials remain ongoing, with further analysis expected.

Will Switzerland fully legalise cannabis?

A national Cannabis Products Act remains a proposal. The consultation opened in August 2025 and closed in December. The proposal envisaged tightly controlled adult access, licensed supply, advertising restrictions and a public-health focus. Those proposals are not current purchase or home-growing permissions.

In its May 8, 2026 account of the legislative work, the National Council’s health committee said it would continue developing the proposal and tasked its subcommittee with revisions. Responses were divided, with concerns about youth protection, implementation burdens and online sales. The committee rejected pausing the work until all pilot evaluations were complete.

The deadline for preparing the legislation was extended to the autumn 2027 session. This is a parliamentary work deadline, not a date when retail sales become legal. Further parliamentary decisions, implementation and any referendum process remain distinct steps. There is no enacted nationwide market-opening date to rely on.

Can tourists buy or use cannabis in Switzerland?

Tourists cannot use the research trials as recreational shops. Eligibility requires residency and formal enrolment, along with each study’s other conditions. Retail availability of low-THC products does not mean every product on a shelf complies with the rules.

Do not assume Swiss possession provisions or a prescription will be recognized abroad. Check the destination and transit-country requirements before carrying a cannabis medicine or CBD product across a border. For broader context, see our guides to European cannabis markets and cannabis tourism.

Which rules matter in practice?

The key questions are whether the product is controlled, whether the activity is authorized and which product-specific rules apply. Medical prescribing, low-THC retail products and non-medical research trials are separate systems. A proposed national law does not merge them or create general recreational access today.